Amorphous calcium carbonate

Drug Profile

Amorphous calcium carbonate

Alternative Names: ACC

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amorphical
  • Class Calcium supplements
  • Mechanism of Action Bone development modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hypoparathyroidism
  • Preclinical Bone metastases

Most Recent Events

  • 22 Feb 2017 Amorphical plans a phase I trial for Solid malignancies (NCT03057314)
  • 29 Sep 2016 Pharmacodynamics data from preclinical study in hypoparathyroidism released by Amorphical before 2015(Amorphical pipeline, September 2016)
  • 29 Sep 2016 Amorphical completes a phase I/II trial in hypoparathyroidism in Israel before 2015 (Amorphical pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top